Roivant accelerates key pipeline timelines; Immunovant raises $550M

Roivant Sciences Ltd.

Brepocitinib NDA filing in dermatomyositis expected early 2026; commercial launch early 2027.
Phase 3 brepocitinib trial in non-infectious uveitis fully enrolled; topline data now H2 2026.
Brepocitinib proof-of-concept in cutaneous sarcoidosis fully enrolled; topline data now H1 2026.
IMVT-1402 potentially registrational trial in D2T RA topline data now expected CY 2026.
Immunovant financing led by Roivant generated ~$550M gross proceeds, extending cash runway to IMVT-1402 launch in GD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.